Pharma BD Deal Intelligence
The collaboration includes a $750 million upfront payment by AbbVie and will focus on the development of three of Genmab's bispecific antibodies for cancer.
AbbVie and Genmab strike a EUR 3.4 billion immuno-oncology megadeal to co-develop three bispecific antibody products including epcoritamab, with AbbVie paying…
AbbVie is paying Danish antibody specialist Genmab $750 million upfront for rights to epcoritamab and other cancer drugs, with total deal value potentially…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
CORRECTION: The originally requested Pfizer/Genmab $1.9B bispecific deal from 2022 does not exist. The landmark Genmab bispecific deal was AbbVie/Genmab, announced June 2020. AbbVie paid $750 million upfront for a broad oncology collaboration to jointly develop and commercialize three bispecific antibody candidates including epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37, and DuoBody-CD3x5T4. Total potential value up to $3.9 billion with development, regulatory, and sales milestones. Companies share US and Japan profits 50:50; Genmab receives 22-26% tiered royalties on ex-US/Japan sales.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Genmab A/S (this deal) | 2020 | $3.9B | 81 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2020 deals · AbbVie Inc. deals · Oncology deals